American Association for Cancer Research

Table 5.

Changes from baseline to 1 mo in the reported thoroughness of SSEs in each group and in the total sample

	Carriers							Noncarriers		Total sample
		CDKN2A/p16⁺ no melanoma history			CDKN2A/p16⁺ melanoma history			CDKN2A/p16⁻ no melanoma history		Total sample
		Baseline	1 mo	Baseline	1 mo	Baseline	1 mo	Baseline	1 mo
Thoroughness of SSEs
SSE thoroughness ratings*	2.67	2.61	3.23	2.77	2.38	2.25	2.71	2.50
No. body sites examined during SSEs^†	5.46	8.82^‡	8.82	7.91	7.41	5.82	7.26	7.26
Frequency of enlistment of another person's assistance in the conduct of SSEs^§	1.91	1.91	2.82	2.27	1.77	1.47	2.10	1.82

	Carriers							Noncarriers		Total sample
		CDKN2A/p16⁺ no melanoma history			CDKN2A/p16⁺ melanoma history			CDKN2A/p16⁻ no melanoma history		Total sample
		Baseline	1 mo	Baseline	1 mo	Baseline	1 mo	Baseline	1 mo
Thoroughness of SSEs
SSE thoroughness ratings*	2.67	2.61	3.23	2.77	2.38	2.25	2.71	2.50
No. body sites examined during SSEs^†	5.46	8.82^‡	8.82	7.91	7.41	5.82	7.26	7.26
Frequency of enlistment of another person's assistance in the conduct of SSEs^§	1.91	1.91	2.82	2.27	1.77	1.47	2.10	1.82

NOTE: Values in boldface indicate significant changes from baseline.

1, I did not pay close attention to my skin; 2, I casually checked my skin, taking a quick overall look; 3, I only looked at particular marks on my skin; and 4, I did a thorough skin exam.

†

Participants used a checklist to indicate whether they had examined each of the following body parts when conducting a SSE: scalp, face, neck, shoulders, back, chest, arms, genitals, legs, feet, and bottoms of feet; they received a score of 1 for each of the 11 body parts checked.

‡

P < 0.01.

1, none of the time; 2, some of the time; 3, about half of the time; 4, most of the time; 5, all of the time.

View Large

This Feature Is Available To Subscribers Only